Who May Sue: Patent Standing Issues and Implications for the Life Sciences Industry (Part I)

Why It Matters

Proper standing determines whether a life‑science firm can enforce its patents, directly affecting its ability to protect R&D investments and monetize innovations. Missteps can lead to costly litigation setbacks and reduced revenue.

Key Takeaways

• Standing determines who may bring patent infringement claims
• Life‑science firms face heightened standing complexities due to licensing
• Clear exclusionary rights prevent dismissal and joinder disputes
• Sublicensing clauses define enforcement authority across corporate affiliates
• Drafting precision safeguards recoverable damages in patent litigation

Pulse Analysis

In U.S. patent law, standing functions as the gatekeeper that decides whether a plaintiff has the legal right to pursue an infringement claim. The Federal Circuit has refined this requirement, insisting that a party must hold a concrete, enforceable interest in the patented invention. For life‑sciences companies, where patents often sit behind complex licensing matrices and collaborative research agreements, establishing that interest can be especially challenging. Misidentifying the proper claimant not only jeopardizes a case’s viability but also wastes valuable resources that could be directed toward product development.

The article stresses that patentees should explicitly allocate exclusionary rights, enforcement authority, and sublicensing permissions when structuring agreements among affiliates, joint‑venture partners, or third‑party licensees. Precise drafting clarifies which entity can sue, prevents inadvertent joinder of parties, and safeguards the full spectrum of recoverable damages. For example, a parent corporation that merely holds a non‑exclusive license may lack the standing to enforce the patent, whereas a subsidiary granted exclusive rights can act as the rightful plaintiff. Such contractual foresight reduces the risk of dismissals and streamlines litigation strategy.

Beyond courtroom tactics, standing considerations influence a life‑sciences firm’s broader IP portfolio management and investment decisions. Companies that embed clear enforcement clauses into their licensing frameworks can more confidently commercialize breakthrough therapies, attract venture capital, and negotiate favorable partnership terms. As the industry moves toward increasingly collaborative R&D models, the need for rigorous standing analysis will only intensify. Part II of the series promises to unpack the Federal Circuit’s step‑by‑step analytical framework, offering practitioners actionable guidance to navigate these evolving legal landscapes.